What side effects are associated with this type of intervention?

Common treatments for Follicular Lymphoma, such as rituximab combined with chemotherapy, can cause a range of side effects. Rituximab is associated with infusion reactions, which can be severe, especially during the first cycle. These reactions may include fever, chills, and respiratory symptoms. Chemotherapy can lead to side effects like alopecia (hair loss), neutropenia (low white blood cell count), anemia, and thrombocytopenia (low platelet count). Bispecific antibodies like Odronextamab may also cause similar infusion-related reactions and immune-related side effects, although specific data on Odronextamab's side effects are still being studied.

What prior FDA approvals exist?

The FDA has approved several treatments for Follicular Lymphoma, particularly those targeting the CD20 antigen on B-cells. Rituximab, a monoclonal antibody targeting CD20, has been a cornerstone in the treatment of Follicular Lymphoma, often used in combination with chemotherapy. Other CD20-targeting monoclonal antibodies include obinutuzumab and ofatumumab. Additionally, bispecific antibodies like mosunetuzumab, which targets both CD20 and CD3, have shown promise in clinical trials, similar to the investigational drug Odronextamab.

What other types of research exist?

Promising, novel alternatives to Odronextamab for Follicular Lymphoma patients include: 1) Bispecific fusion proteins targeting 4-1BB and PD-L1, which aim to enhance the immune response against cancer cells while minimizing dose-limiting toxicities. 2) Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, which has shown superior progression-free survival (PFS) and overall survival (OS) in various subgroups of chronic lymphocytic leukemia (CLL) and may be applicable to follicular lymphoma. 3) Venetoclax, a BCL-2 inhibitor, which has demonstrated efficacy in combination with other agents in hematologic malignancies. These alternatives represent innovative approaches that could be considered in consultation with a healthcare provider.

← Back to Search

Anti-tumor antibiotic

Odronextamab + Chemotherapy for Follicular Lymphoma (OLYMPIA-2 Trial)

Phase 3

Recruiting

Research Sponsored by Regeneron Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have diagnosis of cluster of differentiation 20 positive (CD20+) FL grade 1-3a, stage II bulky or stage III / IV

For Part 2: previously untreated participants who have FLIPI-1 score of 0 to 5

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

OLYMPIA-2 Trial Summary

This trial researches an experimental drug to treat a type of non-Hodgkin lymphoma to assess safety, effectiveness, and side effects.

Who is the study for?

Adults with previously untreated follicular lymphoma can join this trial. They should be able to perform daily activities (ECOG 0-2) and have a certain level of disease severity (FLIPI-1 score). Participants must not have other types of lymphomas, recent major surgeries, organ transplants, or any condition that could risk their safety in the study.Check my eligibility

What is being tested?

The trial is testing odronextamab combined with chemotherapy against the standard rituximab with chemotherapy. It's divided into three parts: initial non-randomized phases to determine safe dosages and a final phase comparing effectiveness between treatments.See study design

What are the potential side effects?

Potential side effects include reactions to odronextamab such as immune responses against the drug, infusion-related symptoms, impact on blood levels and organ function. The study also monitors quality-of-life changes due to treatment.

OLYMPIA-2 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My lymphoma is CD20 positive and is either stage II bulky or stage III/IV.

Select...

My FLIPI score for lymphoma is between 0 and 5, and I haven't been treated yet.

Select...

I am able to get out of my bed or chair and move around.

Select...

My cancer can be measured on a CT or MRI scan.

OLYMPIA-2 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Complete Response rate at 30 months (CR30) assessed by independent central review (ICR)

Incidence of dose limiting toxicities (DLTs) for odronextamab in combination with chemotherapy

Incidence of treatment-emergent adverse events (TEAEs) of odronextamab in combination with chemotherapy

+1 more

Secondary outcome measures

BOR as assessed by ICR

BOR as assessed by local investigator

Best overall response (BOR) as assessed by the investigator

+27 more

OLYMPIA-2 Trial Design

4Treatment groups

Experimental Treatment

Active Control

Group I: Odronextamab + Chemotherapy + No maintenanceExperimental Treatment2 Interventions

In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy (CHOP, or CVP) without maintenance.

Group II: Odronextamab + Chemotherapy + MaintenanceExperimental Treatment2 Interventions

In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy [CHOP, or cyclophosphamide, vincristine, and prednisone (CVP)], followed by odronextamab monotherapy maintenance.

Group III: Odronextamab + ChemotherapyExperimental Treatment4 Interventions

Part 1 of the study includes ordonextamab dose escalation for participants with previously untreated FL and relapsed/refractory FL (Part 1A only) followed by a randomized exploration of 2 regimens of odronextamab (O) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) with the objective of dose optimization (Part 1B) in previously untreated patients with FL.

Group IV: Rituximab + ChemotherapyActive Control6 Interventions

In Part 2 only, participants will be randomized 1:1:1 to receive rituximab (R) with chemotherapy (CHOP), followed by rituximab monotherapy maintenance.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cyclophosphamide

1995

Completed Phase 3

~3770

Doxorubicin

2012

Completed Phase 3

~7940

Vincristine

2003

Completed Phase 4

~2910

0 / 4Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Follicular Lymphoma treatments often target specific proteins on the surface of cancer cells to enhance the immune system's ability to destroy them. Rituximab, a monoclonal antibody, targets the CD20 protein on B-cells, marking them for destruction by the immune system. Odronextamab, an experimental bispecific antibody, targets both CD20 on B-cells and CD3 on T-cells, bringing these cells together to enhance the immune response against the lymphoma. Chemotherapy works by killing rapidly dividing cells, including cancer cells. These targeted therapies are crucial for Follicular Lymphoma patients as they offer more precise and potentially more effective treatment options with potentially fewer side effects compared to traditional chemotherapy.

Find a Location

Who is running the clinical trial?

Regeneron PharmaceuticalsLead Sponsor

634 Previous Clinical Trials

381,315 Total Patients Enrolled

Clinical Trial ManagementStudy DirectorRegeneron Pharmaceuticals

268 Previous Clinical Trials

251,544 Total Patients Enrolled

~489 spots leftby Jan 2030

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.